NCT01301807View on ClinicalTrials.gov

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 28, 2011

Primary Completion Date

November 7, 2019

Study Completion Date

November 7, 2019

Conditions
Non-Secretory Plasma Cell MyelomaPlasmacytosisRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Carfilzomib

Given IV

DRUG

Panobinostat

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01301807 - Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter